BALTIMORE & EXTON, Pa.--(BUSINESS WIRE)--Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development of oncology drugs, and Morphotek®, Inc., a subsidiary of Eisai Inc., have established an agreement to test one of Morphotek’s oncology monoclonal antibodies using Champions’ Biomerk Tumorgraft™ platform.
